Related Experiment Video
Updated: Jul 6, 2026
07:25
Assessing Murine Resistance Artery Function Using Pressure Myography
Published on: June 7, 2013
Endothelin-1 and hypertension: from bench to bedside
1Division of Nephrology, University of Utah Health Sciences Center, 1900 East 30 North, Salt Lake City, UT 84132, USA. donald.kohan@hsc.utah.edu
Current Hypertension Reports
|March 28, 2008
Summary
Endothelin-1 (ET-1) plays a role in hypertension through its receptors. Blocking ET-1 receptors can lower blood pressure in hypertensive patients, but further research is needed.
Area of Science:
- Cardiovascular Physiology
- Endocrinology
- Pharmacology
Background:
- Endothelin-1 (ET-1) influences systemic blood pressure through various biological effects.
- Increased ET system activity in vasculature, primarily activating ET A receptors, contributes to hypertension.
- Reduced renal medullary ET-1 production and collecting duct ET B receptor activation also elevate blood pressure.
Purpose of the Study:
- To explore the role of the endothelin system in hypertension.
- To investigate the therapeutic potential of ET receptor antagonists.
- To address remaining questions regarding ET receptor blockade in hypertension management.
Main Methods:
- Review of recent studies on the ET system and hypertension.
- Analysis of the effects of ET receptor blockers in hypertensive patients.
- Identification of key areas for future research in ET system modulation.
Main Results:
- Both ET A and combined A/B receptor blockers demonstrate blood pressure-lowering effects in hypertensive individuals.
- The ET system's complex role in hypertension involves both vascular and renal components.
- ET receptor antagonists offer a potential therapeutic avenue for managing hypertension.
Conclusions:
- The ET system is a significant factor in the pathophysiology of hypertension.
- Targeting ET receptors, particularly ET A, shows promise for antihypertensive therapy.
- Further investigation is required to understand interactions with other antihypertensives and effects on end-organ damage.
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
01:18Hypertension and Regulation of Blood Pressure
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:17Hormonal Regulation of Blood Pressure
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...